Evidence map›Paper›PMID 32556427›Full record

ArticleExperimental brain research2020

Investigation of promoter methylation of MCPH1 gene in circulating cell-free DNA of brain tumor patients.

Marjan Ghodsi, Mohammadreza Shahmohammadi, Mohammad Hossein Modarressi, Fatemeh Karami

Abstract read
PubMed Publisher
In one paragraph

Article in Experimental brain research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Cell-free DNA-based liquid biopsies in neurology.Brain : a journal of neurology · 2023
    Review
  3. Promoter Methylation of TwoAddiction & health · 2023
    Article
  4. Review
  5. Article
  6. BloodFrontiers in aging neuroscience · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Marjan GhodsiDepartment of Biology, School of Basic Science, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Mohammadreza ShahmohammadiFunctional Neurosurgery Research Center, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Hossein ModarressiDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. modaresi@tums.ac.ir.
Fatemeh KaramiDepartment of Medical Genetics, Applied Biophotonics Research Center, Science and Research Branch, Islamic Azad University, Tehran, Iran. fatemeh.karami@srbiau.ac.ir.
Islamic Azad University, Science and Research Branch · IRShahid Beheshti University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite advanced diagnostic and therapeutic techniques, many brain tumors are still diagnosed at high grades and, therefore finding novel molecular markers may assist in early detection and reducing brain tumors-related mortality rate. Owing to the previous reports on the importance of MCPH1 gene in tumorigenesis, the present study was aimed to study the promoter methylation of MCPH1 gene in paired circulating cell-free DNA (cfDNA) and tumor tissues of brain tumor patients. MATERIALS AND

methodsFourteen fresh paired serum and tumor tissue samples in addition to 18 isolated serum samples were collected from patients affected by different grades of brain tumor. Genomic DNA and cfDNA was isolated from tissue and serum samples using QIAamp DNA Mini Kit Norgen Bioteck Kit, respectively. Methylation DNA immunoprecipitation Real-time polymerization chain reaction (MeDIP-Real-time PCR) was performed on isolated DNA samples using EpiQuik MeDIP Ultra Kit and specific primer pairs. cfDNA quantity was determined through Real-time PCR analysis using specific primer pairs designed for GAPDH gene.

resultsMCPH1 was methylated in 54% of cfDNA samples which was significantly associated with tumor grade, as well (P-value = 0.02). The methylation rate of MCPH1 was found as 78% in the tissue samples which was meaningfully associated with tumor grade (P-value = 0.03). Moreover, methylation of the MCPH1 gene was consistent in 57% of the same cfDNA and tissue samples. Methylation of MCPH1 gene in neither tumor tissues nor cfDNA was not correlated with age and sex of the patients. DISCUSSION AND

conclusionDue to the conformity of methylation of MCPH1 gene in cfDNA and tissue samples in more than half of the enrolled patients, especially in higher grades of tumors, it seems that MCPH1 promoter methylation could be a potential epimarker in not only detection of brain tumors but also in response to chemo- and radiotherapy which warranted further assessment.

Indexed as

Brain NeoplasmsCell-Free Nucleic AcidsBiomarkers, TumorCell Cycle ProteinsCytoskeletal ProteinsDNA MethylationDNA, NeoplasmHumansPromoter Regions, GeneticBiomarkers, TumorCell Cycle ProteinsCell-Free Nucleic AcidsCytoskeletal ProteinsDNA, NeoplasmMCPH1 protein, humanBrain tumorCell-free DNAMCPH1MeDIP-real-time PCRPromoter methylation

Identifiers

PMID32556427
OpenAlexW3035908047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.